Department of Hematology, The Sixth Affiliated Hospital of Wenzhou Medical University, No. 15, Dazhong Road, Liandu District, Lishui, Zhejiang 323000, China.
Department of Hematology, The Sixth Affiliated Hospital of Wenzhou Medical University, No. 15, Dazhong Road, Liandu District, Lishui, Zhejiang 323000, China.
Tissue Cell. 2022 Feb;74:101674. doi: 10.1016/j.tice.2021.101674. Epub 2021 Nov 2.
T-cell acute lymphoblastic leukemia (T-ALL) is a clonal malignant disease. Isocitrate Dehydrogenase 1-R123 (IDH1-R132 H) is related to T-ALL progression. This study explored the role of IDH1-R132H in T-ALL. Molt-4 cells with IDH1-R132H mutation were constructed by retroviral transfection of IDH1-R132H and T-ALL xenotransplantation mouse model was established by injection of Molt-4 cells through the tail vein. Infiltration of the liver, spleen, and bone marrow and the percentage of CD45-positive T-ALL cells in them were detected. Cell proliferation, apoptosis, and invasion were evaluated after the intervention of Notch1, PTEN, or PI3K expression. The leukocyte number was increased, the spleen was enlarged, infiltration in bone marrow, spleen, and liver tissue was worsened and the percentage of hCD45-positive T-ALL cells was increased by IDH1-R132H mutation, which promoted T-ALL deterioration. IDH1-R132H mutation promoted proliferation, invasion, and inhibited apoptosis of T-ALL cells, which were reversed by inhibition of Notch1. IDH1-R132H mutation upregulated HES1 expression and downregulated PTEN expression by activating the Notch1 pathway, while inhibition of Notch1 reversed these changes. PTEN inhibited the PI3K/AKT pathway activation. PTEN overexpression reversed IDH1-R132H mutation effect on promoting malignant behaviors of T-ALL cells. IDH1-R132H mutation inhibited PTEN expression by activating the Notch1/HES1 pathway, activated the PI3K/AKT pathway, thus promoting malignant behaviors of T-ALL cells.
T 细胞急性淋巴细胞白血病(T-ALL)是一种克隆性恶性疾病。异柠檬酸脱氢酶 1-R123(IDH1-R132H)与 T-ALL 进展有关。本研究探讨了 IDH1-R132H 在 T-ALL 中的作用。通过逆转录病毒转染 IDH1-R132H 构建 IDH1-R132H 突变的 Molt-4 细胞,并通过尾静脉注射 Molt-4 细胞建立 T-ALL 异种移植小鼠模型。检测肝脏、脾脏和骨髓的浸润情况以及其中 CD45 阳性 T-ALL 细胞的百分比。干预 Notch1、PTEN 或 PI3K 表达后,评估细胞增殖、凋亡和侵袭情况。IDH1-R132H 突变导致白细胞数量增加,脾脏肿大,骨髓、脾脏和肝脏组织浸润加重,hCD45 阳性 T-ALL 细胞百分比增加,促进 T-ALL 恶化。IDH1-R132H 突变促进 T-ALL 细胞增殖、侵袭,抑制凋亡, Notch1 抑制可逆转这些变化。IDH1-R132H 突变通过激活 Notch1 通路上调 HES1 表达,下调 PTEN 表达,而 Notch1 抑制可逆转这些变化。PTEN 抑制 PI3K/AKT 通路激活。PTEN 过表达逆转 IDH1-R132H 突变对 T-ALL 细胞恶性行为的促进作用。IDH1-R132H 突变通过激活 Notch1/HES1 通路抑制 PTEN 表达,激活 PI3K/AKT 通路,从而促进 T-ALL 细胞的恶性行为。